HC Wainwright Cuts Rockwell Medical (NASDAQ:RMTI) Price Target to $3.00

Rockwell Medical (NASDAQ:RMTI) had its price objective decreased by HC Wainwright from $7.00 to $3.00 in a research report released on Monday morning, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Rockwell Medical’s Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.10) EPS, Q1 2026 earnings at ($0.02) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.06) EPS.

Separately, StockNews.com cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

Rockwell Medical Stock Performance

NASDAQ RMTI opened at $1.24 on Monday. The business’s 50-day moving average price is $1.80 and its 200 day moving average price is $2.57. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. Rockwell Medical has a twelve month low of $1.18 and a twelve month high of $5.15. The company has a market capitalization of $40.08 million, a PE ratio of -24.80 and a beta of 1.55.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.04). Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%. The company had revenue of $24.67 million for the quarter, compared to analysts’ expectations of $23.65 million. On average, research analysts predict that Rockwell Medical will post 0.03 earnings per share for the current year.

Institutional Trading of Rockwell Medical

A number of institutional investors have recently modified their holdings of RMTI. Raymond James Financial Inc. purchased a new position in Rockwell Medical in the fourth quarter valued at approximately $28,000. Two Sigma Securities LLC acquired a new stake in shares of Rockwell Medical in the fourth quarter worth $33,000. Barclays PLC raised its stake in shares of Rockwell Medical by 27.5% in the 4th quarter. Barclays PLC now owns 28,854 shares of the company’s stock valued at $59,000 after acquiring an additional 6,229 shares during the period. XTX Topco Ltd lifted its holdings in shares of Rockwell Medical by 58.0% during the 4th quarter. XTX Topco Ltd now owns 44,962 shares of the company’s stock valued at $92,000 after acquiring an additional 16,507 shares in the last quarter. Finally, LPL Financial LLC boosted its position in Rockwell Medical by 91.3% during the 4th quarter. LPL Financial LLC now owns 54,872 shares of the company’s stock worth $112,000 after purchasing an additional 26,191 shares during the period. Hedge funds and other institutional investors own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.